Wednesday, July 29, 2026 - KFF Health News
- Betting platforms Kalshi and Polymarket now allow users to wager on whether the FDA will approve treatments for lung, breast, pancreas, and blood cancers this year.
- Kalshi intends to expand its offerings by allowing users to bet on the specific outcomes of clinical drug trials.
- Simultaneously, the FDA has reiterated concerns regarding Replimune's lack of adequate data as the biotech company attempts for a third time to gain clearance for a controversial skin cancer drug.
- These developments highlight a growing trend of financial speculation surrounding regulatory health decisions and the ongoing struggle for high-risk biotech approvals.
Sources & Citations
1 sourceMore Stories
Medical Bulletin 04/August/2026
• Researchers have discovered that genetic factors may determine why certain individuals suffer more significant brain damage from chronic sleep deprivation than others. • A preliminary study suggests that the lycopene and antioxidants in tomatoes may reduce oxidative stress and improve liver fat metabolism in people with MASLD.
Read original · medicaldialogues.inWhat we’ve learned about Covid-19 since the pandemic
• Since the initial reporting of Covid-19, medical understanding has evolved significantly regarding the virus's behavior and the effectiveness of countermeasures. • In December 2020, the US FDA granted emergency use authorization to Pfizer/BioNTech and Moderna vaccines after clinical trials demonstrated over 90% efficacy in preventing symptomatic disease.
Read original · edition.cnn.com
CNNFDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
• The FDA is currently reviewing Moderna's mRNA-based flu vaccine, which would be the first of its kind to enter the commercial market. • This decision comes amid a climate of skepticism regarding mRNA technology, highlighted by questions from RFK Jr. and recent HHS funding cuts.
Read original · npr.orgHelus Pharma Appoints CEO Ahead of Expected Q4 2026 Data
• Helus Pharma has appointed a new CEO to lead the company as it advances its lead candidate, HLP003, toward potential commercialization. • The company announced that enrollment is now complete for the APPROACH clinical trial, with topline data expected to be released in Q4 2026.
Read original · stocktitan.net
Stock TitanMonday, August 3, 2026 - KFF Health News
• The Department of Veterans Affairs is launching a randomized clinical trial to determine if GLP-1 drugs can reduce alcohol abuse among U.S. military veterans. • The study will specifically measure whether semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, can decrease drinking and improve overall quality of life.
Read original · kffhealthnews.orgMedical Bulletin 03/August/2026
• A new medical review suggests that reducing protein consumption may slow biological aging and extend lifespan by improving metabolism and lowering inflammation. • Research indicates that protein restriction preserves healthy cell function and reduces cellular damage, with similar benefits previously observed in flies and rodents.
Read original · medicaldialogues.inMental Health News -- ScienceDaily
• New research indicates that individuals using cannabis for self-medication face increased risks of paranoia and typically consume higher levels of THC. • The study highlights that childhood trauma further amplifies these psychological risks, creating a more dangerous interaction for vulnerable users.
Read original · sciencedaily.comA Timeline of COVID-19 Developments in 2020
• COVID-19 dominated the global landscape throughout 2020, evolving from an emerging health crisis to a pandemic that concluded the year with the arrival of vaccines. • Overwhelmed hospitals struggled with severe resource shortages, specifically lacking enough personal protective equipment (PPE) to maintain standard operations.
Read original · ajmc.comHHS releases government-wide policy to prohibit gain-of-function research - The Cancer Letter
• The Trump Administration and the Department of Health and Human Services (HHS) have released the "United States Government Policy for Stopping High-Risk Life Sciences Research." • This new framework explicitly prohibits federally supported gain-of-function research that is deemed dangerous to public health.
Read original · cancerletter.com
The Cancer LetterReuters Health News Summary
• An FDA advisory panel voted on Thursday to support trial results for Replimune's drug, RP1, which targets a specific type of skin cancer. • The FDA had previously declined to approve RP1 twice, most recently in April, due to a lack of a control group and insufficient evidence of effectiveness.
Read original · devdiscourse.com
DevdiscourseCyclosporiasis Outbreak 2026: 145 Cases Across 17 States, CDC Alert for Health Care Workers
• A Cyclosporiasis outbreak has been reported across 17 states, with 145 confirmed cases of the gastrointestinal disease caused by the Cyclospora parasite. • The CDC has issued an alert to health care workers to ensure rapid diagnosis and proper response, as the infection spreads via contaminated food or water.
Read original · infectioncontroltoday.com